Developmental therapeutics for patients with breast cancer and central nervous system metastasis: Current landscape and future perspectives

R. Costa*, B. A. Carneiro, D. A. Wainwright, C. A. Santa-Maria, P. Kumthekar, Y. K. Chae, W. J. Gradishar, M. Cristofanilli, F. J. Giles

*Corresponding author for this work

Research output: Contribution to journalReview article

13 Scopus citations

Abstract

Breast cancer is the second-leading cause of metastatic disease in the central nervous system (CNS). Recent advances in the biological understanding of breast cancer have facilitated an unprecedented increase of survival in a subset of patients presenting with metastatic breast cancer. Patients with HER2 positive (HER2+) or triple negative breast cancer are at highest risk of developing CNS metastasis, and typically experience a poor prognosis despite treatment with local and systemic therapies. Among the obstacles ahead in the realm of developmental therapeutics for breast cancer CNS metastasis is the improvement of our knowledge on its biological nuances and on the interaction of the blood-brain barrier with new compounds. This article reviews recent discoveries related to the underlying biology of breast cancer brain metastases, clinical progress to date and suggests rational approaches for investigational therapies.

Original languageEnglish (US)
Pages (from-to)44-56
Number of pages13
JournalAnnals of Oncology
Volume28
Issue number1
DOIs
StatePublished - Jan 1 2017

Keywords

  • Anti-angiogenesis
  • Brain
  • Breast cancer
  • HER2
  • Immunotherapy
  • Targeted therapy

ASJC Scopus subject areas

  • Hematology
  • Oncology

Fingerprint Dive into the research topics of 'Developmental therapeutics for patients with breast cancer and central nervous system metastasis: Current landscape and future perspectives'. Together they form a unique fingerprint.

  • Cite this